Teacher Retirement System of Texas Buys 1,271 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Teacher Retirement System of Texas boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 19.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,904 shares of the company’s stock after acquiring an additional 1,271 shares during the quarter. Teacher Retirement System of Texas’ holdings in Tarsus Pharmaceuticals were worth $438,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TARS. Intech Investment Management LLC bought a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at about $282,000. Charles Schwab Investment Management Inc. lifted its stake in Tarsus Pharmaceuticals by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company’s stock valued at $9,538,000 after acquiring an additional 28,130 shares in the last quarter. FMR LLC boosted its position in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after acquiring an additional 3,537 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Tarsus Pharmaceuticals by 10.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company’s stock worth $1,935,000 after acquiring an additional 5,709 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $763,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares in the company, valued at approximately $2,687,458.53. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the sale, the insider now owns 50,751 shares of the company’s stock, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $51.37 on Tuesday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The business’s 50 day moving average price is $49.10 and its two-hundred day moving average price is $46.34. The company has a market cap of $1.97 billion, a PE ratio of -13.48 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. On average, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of analyst reports. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. HC Wainwright reissued a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Finally, Guggenheim reissued a “buy” rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.